To evaluate the effectiveness of ctDNA monitoring in predicting relapse and survival outcomes in early breast cancer patients compared to standard treatment response measures.
Key Findings:
Persistence of ctDNA after neoadjuvant therapy was strongly associated with recurrence and death.
Patients with cleared ctDNA during treatment had significantly better outcomes.
ctDNA dynamics were more prognostic than pathologic complete response.
ctDNA detection often preceded clinical relapse by a median of 13.8 months.
